Canakinumab
Anti–IL-1β monoclonal antibody
- Response rate
- High (RCT confirmed)
- Onset
- Days–weeks
- Route
- SC 150mg every 4–8 weeks
- Line
- 2nd
- IgM effect
- No effect
Evidence summary
Directly neutralises IL-1β with long half-life. The only RCT in Schnitzler (Krause et al. 2015) demonstrated sustained efficacy. De Koning et al. 2013 showed sustained remission in a 9-month trial.
Molecular targets (1)
| Molecule | Role | Expression | Evidence |
|---|---|---|---|
| IL-1β | Central pathogenic driver | Elevated | established |